Bydureon: weekly exenatide injection launched

A prolonged-release preparation of exenatide has been launched. Bydureon is administered at a dose of 2mg once weekly by subcutaneous injection. Both Bydureon and Byetta, the existing twice-daily preparation of exenatide, are licensed for use in combination with other oral hypoglycaemics in type II diabetes.

Bydureon has been investigated in 1525 patients in 4 key studies: 2 studies comparing exenatide twice daily against once weekly administration; 1 study comparing against sitagliptin or pioglitazone; and 1 study comparing with insulin glargine. Bydureon was more effective at reducing HBA1c levels than comparator treatment in all 4 studies.

Exenatide is contraindicated in renal impairment: Bydureon in patients with creatinine clearance less than 50ml/min; Byetta may be used with caution in these patients but is contraindicated if creatinine clearance is less than 30ml/min.

View Bydureon drug record

Further Information: Lilly Eli & Co

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Already registered?
Sign in

More from MIMS

Live updates: Coronavirus (COVID-19) in the UK

Live updates: Coronavirus (COVID-19) in the UK

Use our timeline to follow the latest coronavirus developments...

Experts urge vitamin D supplementation and call for research into possible COVID-19 benefits
Drug shortages - live tracker

Drug shortages - live tracker

Use our constantly updated shortages tracker to check...

New rapidly acting insulin launched

New rapidly acting insulin launched

Lyumjev is a new 'ultra rapidly acting' formulation...